Kathleen Tenner
About
Kathleen Tenner is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Kathleen Tenner has authored 30 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 11 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kathleen Tenner's work include HER2/EGFR in Cancer Research (23 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Cancer Treatment and Pharmacology (8 papers). Kathleen Tenner is often cited by papers focused on HER2/EGFR in Cancer Research (23 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Cancer Treatment and Pharmacology (8 papers). Kathleen Tenner collaborates with scholars based in United States, United Kingdom and Spain. Kathleen Tenner's co-authors include Amylou C. Dueck, Edith A. Perez, Monica M. Reinholz, Robert B. Jenkins, Karla V. Ballman, Julie R. Gralow, David W. Hillman, Nancy E. Davidson, Edith A. Perez and George W. Sledge and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.
In The Last Decade
Kathleen Tenner
30 papers receiving 775 citations
Peers
Kathleen Tenner
Roberto Salgado Belgium
Harukaze Yamamoto Japan
Eleonora Nicolò Italy
Géraldine Gebhart Belgium
Jill J.J. Geenen Netherlands
Merdol Ibrahim United Kingdom
Aruna Mani United States
Monika Patre Switzerland
France Blanchard France
J. Goeminne Belgium
Citations per year, relative to Kathleen Tenner Kathleen Tenner (= 1×)
peers
Roberto Salgado
Countries citing papers authored by Kathleen Tenner
Since
Specialization
Citations
This map shows the geographic impact of Kathleen Tenner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Tenner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Tenner more than expected).
Fields of papers citing papers by Kathleen Tenner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kathleen Tenner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Tenner. The network helps show where Kathleen Tenner may publish in the future.
Co-authorship network of co-authors of Kathleen Tenner
This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Tenner. A scholar is included among the top collaborators of Kathleen Tenner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Tenner. Kathleen Tenner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chumsri, Saranya, Joseph J. Larson, Kathleen Tenner, et al.. (2025). Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 31(10). 1885–1893.
2.
Chumsri, Saranya, Joseph J. Larson, Kathleen Tenner, et al.. (2023). Abstract P4-01-17: Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer. Cancer Research. 83(5_Supplement). P4–1.
3.
Haddad, Tufia C., Jun He, Ciara C. O’Sullivan, et al.. (2021). Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). Breast Cancer Research and Treatment. 188(2). 477–487.
4.
Polley, Mei‐Yin C., Maura N. Dickler, Jason P. Sinnwell, et al.. (2021). A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Research and Treatment. 189(1). 15–23.
5.
Norton, Nadine, Kathleen Tenner, Karla V. Ballman, et al.. (2018). Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research. 20(1). 52–52.
6.
Reinholz, Monica M., Beiyun Chen, Amylou C. Dueck, et al.. (2017). IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clinical Cancer Research. 23(15). 4203–4211.
7.
Shah, Mithun Vinod, Anne E. Wiktor, Reid G. Meyer, et al.. (2016). Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. Journal of Clinical Oncology. 34(29). 3502–3510.
8.
Knutson, Keith L., Raphael Clynes, Barath Shreeder, et al.. (2016). Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Research. 76(13). 3702–3710.
9.
Perez, Edith A., Karla V. Ballman, Afshin Mashadi-Hossein, et al.. (2016). Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. JNCI Journal of the National Cancer Institute. 109(2). djw207–djw207.
10.
Perez, Edith A., E. Aubrey Thompson, Karla V. Ballman, et al.. (2015). Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology. 33(7). 701–708.
11.
Norton, Nadine, Mark D. Pegram, Kathleen Tenner, et al.. (2014). Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunology Research. 2(10). 962–969.
12.
Perez, Edith A., E. Aubrey Thompson, S. Keith Anderson, et al.. (2014). Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.. Journal of Clinical Oncology. 32(15_suppl). 509–509.
13.
Haluska, Paul, Albert M. Bernath, Karla V. Ballman, et al.. (2014). Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).. Journal of Clinical Oncology. 32(15_suppl). 632–632.
14.
Ballman, Karla V., Maria Vassilakopoulou, Amylou C. Dueck, et al.. (2014). EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. British Journal of Cancer. 111(6). 1065–1071.
15.
Dueck, Amylou C., Monica M. Reinholz, Xochiquetzal J. Geiger, et al.. (2013). Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831. Clinical Cancer Research. 19(20). 5798–5807.
16.
Moreno‐Aspitia, Alvaro, David W. Hillman, Kathleen Tenner, et al.. (2013). Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 119(15). 2675–2682.
17.
Moreno‐Aspitia, Alvaro, Amylou C. Dueck, Tejal Patel, et al.. (2013). RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Research and Treatment. 138(2). 427–435.
18.
Reinholz, Monica M., Kathleen Tenner, David W. Hillman, et al.. (2011). Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437. Clinical Cancer Research. 17(22). 7183–7193.
19.
Perez, Edith A., Amylou C. Dueck, Ann E. McCullough, et al.. (2011). Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. JNCI Journal of the National Cancer Institute. 104(2). 159–162.
20.
Perez, Edith A., Monica M. Reinholz, David W. Hillman, et al.. (2010). HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology. 28(28). 4307–4315.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Roberto Salgado Breakdown of academic impact, for papers by Harukaze Yamamoto Breakdown of academic impact, for papers by Eleonora Nicolò Breakdown of academic impact, for papers by Géraldine Gebhart Breakdown of academic impact, for papers by Jill J.J. Geenen Breakdown of academic impact, for papers by Merdol Ibrahim Breakdown of academic impact, for papers by Aruna Mani Breakdown of academic impact, for papers by Monika Patre Breakdown of academic impact, for papers by France Blanchard Breakdown of academic impact, for papers by J. Goeminne